Detection of SGI1/PGI1 Elements and Resistance to Extended-Spectrum Cephalosporins in Proteae of Animal Origin in France by Eliette Schultz et al.
fmicb-08-00032 January 18, 2017 Time: 17:9 # 1
ORIGINAL RESEARCH
published: 19 January 2017
doi: 10.3389/fmicb.2017.00032
Edited by:
Daniela Ceccarelli,
Wageningen Bioveterinary Research,
Netherlands
Reviewed by:
Nicolas Carraro,
University of Lausanne, Switzerland
Genevieve Garriss,
Karolinska Institutet, Sweden
*Correspondence:
Marisa Haenni
marisa.haenni@anses.fr
Specialty section:
This article was submitted to
Antimicrobials, Resistance
and Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 06 October 2016
Accepted: 06 January 2017
Published: 19 January 2017
Citation:
Schultz E, Cloeckaert A, Doublet B,
Madec J-Y and Haenni M (2017)
Detection of SGI1/PGI1 Elements
and Resistance
to Extended-Spectrum
Cephalosporins in Proteae of Animal
Origin in France.
Front. Microbiol. 8:32.
doi: 10.3389/fmicb.2017.00032
Detection of SGI1/PGI1 Elements
and Resistance to
Extended-Spectrum Cephalosporins
in Proteae of Animal Origin in France
Eliette Schultz1,2, Axel Cloeckaert1, Benoît Doublet1, Jean-Yves Madec2 and
Marisa Haenni2*
1 Infectiologie et Santé Publique, Institut National de la Recherche Agronomique, Université François Rabelais de Tours,
UMR 1282, Nouzilly, France, 2 Université Lyon-Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement
et du Travail, Unité Antibiorésistance et Virulence Bactériennes, Lyon, France
Proteae, and especially Proteus mirabilis, are often the cause of urinary tract infections
(UTIs) in humans. They were reported as carriers of extended-spectrum β-lactamase
(ESBL) genes, and recently of carbapenemases, mostly carried by the Salmonella
genomic island 1 (SGI1) and Proteus genomic island 1 (PGI1). Proteae have also
lately become an increasing cause of UTIs in companion animals, but antimicrobial
susceptibility data in animals are still scarce. Here, we report the characterization of 468
clinical epidemiologically unrelated Proteae strains from animals collected between 2013
and 2015 in France. Seventeen P. mirabilis strains (3.6%) were positive for SGI1/PGI1
and 18 Proteae (3.8%) were resistant to extended-spectrum cephalosporins (ESC). The
28 isolates carrying SGI1/PGI1 and/or ESC-resistance genes were isolated from cats,
dogs, and horses. ESBL genes were detected in six genetically related P. mirabilis
harboring blaVEB−6 on the SGI1-V variant, but also independently of the SGI1-V, in
3 P. mirabilis strains (blaVEB 6 and blaCTX M 15) and 1 Providencia rettgeri strain− − −
(blaCTX M 1). The AmpC resistance genes blaCMY 2 and/or blaDHA 16 were detected in− − − −
9 P. mirabilis strains. One strain presented both an ESBL and AmpC gene. Interestingly,
the majority of the ESBL/AmpC resistance genes were located on the chromosome.
In conclusion, multiple ESC-resistance genetic determinants are circulating in French
animals, even though SGI1-V-carrying P. mirabilis seems to be mainly responsible for
the spread of the ESBL gene blaVEB−6 in dogs and horses. These results are of public
health relevance and show that companion animals in close contact with humans should
be regarded as a potential reservoir of ESC-resistant bacteria as well as a reservoir of
ESC-resistance genes that could further disseminate to human pathogens.
Keywords: SGI1, PGI1, Proteus, ESBL, AmpC, animal, dog
INTRODUCTION
Proteae are specific Enterobacteriaceae comprising bacterial species present in water, soil or in
the intestinal tract of humans and animals. In humans, Proteae, and especially Proteus mirabilis,
are often the cause of urinary tract infections (UTIs; Schaffer and Pearson, 2015). They are
otherwise opportunistic pathogens responsible for various infections ranging from minor to
life-threatening issues. In veterinary medicine, P. mirabilis and other Proteae are rarely found
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as pathogens except as a cause of UTIs in companion
animals (Bubenik et al., 2007). This pathology is only rarely
treated with extended-spectrum cephalosporins (ESC), and the
recommended antibiotics are sulphonamides, aminoglycosides,
or fluoroquinolones.
Proteus mirabilis is naturally susceptible to β-lactams and
β-lactamases inhibitors (Stock, 2003). In the late 1990s,
the emergence of P. mirabilis isolates expressing acquired
β-lactamases was first reported in France (Chanal et al., 2000).
Extended-spectrum (ESBL) and AmpC β-lactamases are of a
critical importance because they both confer resistance to nearly
all β-lactams, including ESC. Interestingly, even though the
corresponding genes (mostly blaCTX−M−types and blaVEB−6 for
ESBL and blaCMY−2 and blaDHA−16 for AmpC) are generally
located on plasmids which allow an easy intra- or inter-
species dissemination, several studies revealed chromosome-
encoded ESBL/AmpC genes in P. mirabilis (Song et al., 2011;
Harada et al., 2012). These chromosome-encoded genes are
often carried by genomic islands (such as the Salmonella
Genomic Island 1, SGI1) or integrating conjugative elements
(ICEs) that may also be transmitted (Harada et al., 2010; Mata
et al., 2011). While ESBL-producing P. mirabilis are nowadays
commonly isolated from humans, the first CTX-M-55-producing
P. mirabilis in animals was only reported in 2011 from a
macaque imported from Vietnam to France (Dahmen et al.,
2013).
Besides, P. mirabilis can also carry various genomic islands
conferring multidrug resistance. For example SGI1, the genomic
island widely disseminated in Salmonella, was first identified in
a clinical P. mirabilis from a diabetic patient from Palestine in
2006 (Ahmed et al., 2007). SGI1 is a site-specific integrative
mobilizable element conferring multidrug resistance initially
described in Salmonella enterica serovar Typhimurium DT104
(Boyd et al., 2001).
Salmonella genomic island 1 is the first MDR genomic island
identified in S. enterica, and contains a complex class 1 integron,
named In104 (Hall, 2010). Since the identification of SGI1 in
S. Typhimurium DT104, more than 30 different SGI1 variants
carrying different combinations of antimicrobial resistance genes
were described so far (Hall, 2010). The complex In104 integron
variants classically possess one or two cassette attachment sites
(attI1) carrying various resistance gene cassette arrays, contain
an IS6100 element, may contain additional resistance genes, and
are bound by 25-bp inverted repeats IRi and IRt (Boyd et al.,
2001) (Figure 1). In the great majority of these variants, the
complex In104 integron or its variants are found always at the
same position in the SGI1 scaffold, i.e., between the resolvase
gene res (also named tnpR) and the open reading frame (ORF)
S044 at the 3′ end of SGI1 (Hall, 2010). A few additional
variations occurred in the SGI1 backbone of some variants,
especially the insertion/deletion created by ISVch4 between ORF
S005 and S009 that was found in several SGI1 variants (SGI1-
H, -Ls, -Ks, -Ps, Qs, -PmABB, and -PmMAT) in S. enterica
and P. mirabilis (Doublet et al., 2008; Siebor and Neuwirth,
2013).
Salmonella genomic island 1 is found integrated most of the
time within the last 18 bp of the well-conserved chromosomal
trmE gene (also named thdF). SGI1 is specifically mobilized in
trans by conjugative plasmids of the IncA/C family (Doublet
et al., 2005). Only this plasmid family has been shown to
be able to mobilize SGI1 (Douard et al., 2010). The main
reason of this specificity is that the SGI1 excision from the
chromosome is triggered by the master activator AcaDC encoded
by IncA/C conjugative plasmids (Carraro et al., 2014; Kiss et al.,
2015). Then, as an extrachromosomal form, SGI1 is able to
hijack the conjugative apparatus encoded by IncA/C plasmids
to be conjugally transferred to a recipient cell (Carraro et al.,
2014).
Since 2006, P. mirabilis strains carrying different SGI1 variants
have only been reported in China and France (Boyd et al., 2008;
Siebor and Neuwirth, 2013; Qin et al., 2015). Importantly, the
SGI1-V variant, which is specifically found in P. mirabilis, harbors
the blaVEB−6 gene and was first reported in a lethal human case
in France (Siebor and Neuwirth, 2011).
Recently, a new multidrug resistant genomic island named
Proteus Genomic Island 1 (PGI1) was described in human
P. mirabilis isolates in France (Siebor and Neuwirth, 2014).
A specific PGI1 variant, PGI1-PmPEL, was shown to harbor
both the blaVEB−6 gene and the carbapenemase-encoding gene
blaNDM−1 (Girlich et al., 2015). P. mirabilis isolates of animal
origin were also shown to carry SGI1 or PGI1. Indeed, SGI1-
positive P. mirabilis isolates were reported in poultry and swine
farms in China (Lei et al., 2014, 2015). In France, we recently
described the very first cases of SGI1 (including the VEB-6-
producing SGI1-V variant) or PGI1-positive P. mirabilis in dogs
(Schultz et al., 2015).
The SGI1/PGI1-positive P. mirabilis isolates reported in
animals and humans so far were sporadic cases. Considering
the apparent emergence of these genetic determinants in
P. mirabilis, our aim was to investigate the prevalence of
SGI1 and PGI1 in Proteae of animal origin in France, and
to characterize molecularly the collected strains. In line with
recent observations that a SGI1-V-carrying P. mirabilis clonal
population was shared between humans and animals, we also
investigated the genetic relationship of those isolates in order
to draw hypotheses on a possible transfer between the two
populations. Finally, as these islands in P. mirabilis isolates
were also shown to occasionally capture ESBL or carbapenemase
genes, we investigated the global prevalence of those genes in the
same collection.
MATERIALS AND METHODS
Bacterial Strains and Antibiotic
Susceptibility Testing
Between April, 2013 and February, 2015, a total of 468
clinical non-duplicate Proteae isolates (P. mirabilis, n = 459;
P. vulgaris, n = 1; P. penneri, n = 1; Morganella morganii,
n = 2; Providencia rettgeri, n = 4; P. stuartii, n = 1) were
collected from various animal hosts corresponding to distinct
and epidemiological unrelated individuals (dogs, n = 411; cats,
n = 25; horses, n = 13; bovine, n = 7; rabbit, n = 3;
ovine, n = 3; ferret, n = 2; snake, n = 2; chicken; n = 1;
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FIGURE 1 | Schematic view of SGI1 in the Proteus mirabilis chromosome. (A) Specific genetic traits of the SGI1 structure, the genetic rearrangement due to
ISVch4, and the complex class 1 integrons are represented in frames. Genes and ORFs are shown as arrows, with their orientations of transcription indicated by the
arrowheads. Black arrows indicate antibiotic resistance genes. White arrows within boxes represent insertion sequence elements. IRi and IRt are 25-bp imperfect
inverted repeats defining the integrase and tni ends of complex class 1 integrons. The complex class 1 integrons were drawn from PCR mapping results and
GenBank accession numbers AF261825 (SGI1), HQ888851 (SGI1-V), AY458224 (SGI1-H), and JX121638 (SGI1-PmABB). (B) Schematic view of PGI1 in the
P. mirabilis chromosome. PCRs carried out to map the PGI1 backbone and junctions with the chromosome are indicated by thick black bars. Gray and white arrows
represent the chromosomal genes and the backbone of the island, respectively.
bird, n = 1) and originating from distant geographical areas
throughout France. These isolates were collected through
the Resapath, the French antimicrobial resistance surveillance
network in animal pathogens1. Identification was performed
by peripheral veterinary laboratories and then confirmed at
the Anses laboratory in Lyon, France, using Api20E strips
(bioMérieux, Marcy l’Etoile, France). Isolates were screened for
antibiotic resistance by the disk diffusion method according to
the guidelines of the CA-SFM with 30 antibiotics of veterinary or
human interest2.
SGI1/PGI1 Detection and PCR Mapping
Salmonella genomic island 1 detection was performed by
PCR amplification with degenerated primers designed
in order to amplify all known SGI1 and PGI1 integrase
genes (FwintSGI1HR, 5′ATGTTGCGTCAGGCYGAGGC;
RvintSGI1HR, 5′GAGTGYCCAAGAAGSCGAGAG). The
chromosomal location was confirmed by PCR amplification of
the left and right junctions in the chromosome, as previously
described (Schultz et al., 2015). The genetic diversity of SGI1
was assessed by PCR mapping covering the entire island using
primers previously described (Siebor and Neuwirth, 2011, 2013).
PGI1 detection, chromosomal location, backbone mapping and
resistance gene detection were performed by PCR, as previously
described (Figure 1) (Siebor and Neuwirth, 2014).
1www.resapath.anses.fr
2www.sfm-microbiologie.org
Identification and Genetic Location of
ESBL and AmpC Genes
β-lactamase genes detection was performed by PCR, as
previously described (Dallenne et al., 2010). For the CTX-
M-1 group, an additional PCR was performed using external
primers (ISEcp1L1, 5′ CAGCTTTTATGACTCG; P2D, 5′
CAGCGCTTTTGCCGTCTAAG) and the amplicons were
sequenced.
The chromosomal location of these genes was assessed
with the I-CeuI (New England Biolabs, Hertfordshire, UK)
technique (Liu et al., 1993). After digestion of the complete
DNA, DNA fragments were separated by Pulsed-Field Gel
Electrophoresis (PFGE) in TBE 0.5 X at 14◦C using a CHEF
Mapper (Bio-Rad Laboratories, Richmond, CA, USA). Running
conditions were 6 V/cm with a switch time of 5.3–49.9 s
for 19.7 h. Southern blots were performed by transferring
the DNA on a Hybond-N+ membrane and hybridizing the
membrane with DIG-labeled probes specific for the 23S rDNA,
the ESBL (blaVEB−6, blaCTX−M−1, or blaCTX−M−15) and AmpC
(blaCMY−2 or blaDHA−16) genes of interest (see detailed primers
in Supplementary Table S1). Probes were prepared by PCR
using labeled DIG-dUTP (PCR DIG probe synthesis kit; Roche
Diagnostics, Indianapolis, IN, USA). Detection was performed
using the DIG DNA Labeling and Detection Kit (Roche
Diagnostics) according to the manufacturer’s instructions.
The plasmidic location of these genes was assessed by
Southern blots on S1-PFGE gels (New England Biolabs,
Hertfordshire, UK). Running conditions were 6 V/cm with a
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switch time of 1–30 s for 20 h. Hybridization was performed
as described above for Southern blots on I-CeuI gels, using
the same ESBL/AmpC probes and the DIG DNA Labeling and
Detection Kit.
Finally, all SGI1/PGI1-positive, ESBL and AmpC strains were
analyzed by PCR-based replicon typing (PBRT kit; Diatheva,
Fano, Italy) in order to type the plasmids carrying the
ESBL/AmpC genes.
Genetic Relationship of the Isolates
The genetic diversity was investigated by PFGE. DNA plugs were
digested with SmaI (Promega, Madison, WI, USA) and genomic
DNA was separated by CHEF Mapper gel electrophoresis in
TBE 0.5 X at 14◦C. The running conditions were 6 V/cm with
a switch time of 5–20 s for 22 h. XbaI-digested S. enterica
serovar Braenderup strain H9812 was used as size ladder.
The DNA patterns were analyzed using BioNumerics software
version 4.5 (Applied Maths, Sint-Martens-Latem, Belgium) to
construct a phylogenetic tree. Analysis was performed using
the Dice coefficient with optimization set at 0.5% and tolerance
at 1%.
RESULTS AND DISCUSSION
Prevalence and Molecular
Characterization of the SGI1/PGI1
Genomic Islands
Salmonella genomic island 1/Proteus genomic island 1-carrying
P. mirabilis are emerging pathogens in humans and animals. In
a recent study, SGI1/PGI1-carrying P. mirabilis were reported
in animals in France but no large-scale non-biased data on
their prevalence were available (Schultz et al., 2015). Here, we
investigated a large collection of 468 Proteae isolates of animal
origin in France to estimate the prevalence of the SGI1/PGI1
elements. We also assessed the prevalence of resistance to broad-
spectrum cephalosporins in those Proteae isolates considering
that the blaVEB−6 gene was recurrently reported on the SGI1-V
variant in P. mirabilis (Siebor and Neuwirth, 2011; Schultz et al.,
2015). Among the 468 isolates studied, 17 P. mirabilis (17/468,
3.6%) were positive for SGI1 (11 isolates) or PGI1 (6 isolates) by
PCR (Figure 2 and Table 1). They were mostly recovered from
dogs (n = 13; 13/411, 3.2%), but also from cats (n = 2; 2/25,
8%), and horses (n = 2; 2/13, 15.4%). While Proteae are more
FIGURE 2 | Analysis of SmaI-Pulsed-Field Gel Electrophoresis (PFGE) patterns obtained from the relevant P. mirabilis isolates. PFGE profiles were
compared using BioNumerics software version 4.5 (Applied Maths) with settings of 0.5% optimization and 1.0% tolerance. DNA of S. enterica serovar Braenderup
strain H9812 was used as standard size marker in PFGE experiments and as outgroup in analysis (Hunter et al., 2005). The isolates in bold correspond to previously
published profiles included for comparison purposes (Schultz et al., 2015).
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TABLE 1 | Antibiotic resistance profiles of Proteus mirabilis strains of interest in this study.
Strain Isolation date (yyyy/mm/dd) Host Geographic areab Pathology Antibiotic resistance profilea
34146 2013/04/17 dog Haute-Savoie Urinary tract infection ESBL; StrKanAprTobNetSss
34381 2013/10/09 dog Alpes-Maritimes Urinary tract infection AmpC; Chl
34955 2013/11/22 horse Oise Skin infection ESBL; KanTobNetChlSssTmpNalEnr
34956 2013/10/25 horse Calvados Skin infection ESBL; StrKanTobNetChlSssTmpNalEnr
34958 2013/07/30 dog Paris Urinary tract infection ESBL; StrKanAmkAprGenTobNetChlSssTmpNalEnr
36016 2013/11/05 dog Val-de-Marne Abdominal infection ESBL; StrKanAmkGenTobNetChlSssTmpNalEnr
36017 2013/22/04 dog Val-de-Marne Urinary tract infection ESBL; StrKanGenTobNetChlSssTmpNalEnr
36022 2013/11/10 dog Alpes-Maritimes Urinary tract infection StrSss
36544 2014/03/05 dog Paris Urinary tract infection StrChlSssTmpNalEnr
37427 2014/04/04 dog Val-de-Marne Urinary tract infection ESBL; KanGenTobNetChlSssTmpNalEnr
37429 2014/03/14 dog Loire Otitis StrKanGenTobChlSss
37665 2014/04/22 dog Paris Urinary tract infection AmpC
37666 2014/03/21 dog Val-de-Marne Wound AmxStrKanGenTobSssTmpNalEnr
38309 2014/09/09 dog Haute-Savoie Unknown StrSssTmpNalEnr
38317 2014/09/09 dog Tarn Otitis AmxStrKanGenTobChlSssTmpNalEnr
38327 2014/09/29 dog Oise Skin infection ESBL + AmpC; StrKanChlSssTmp
38346 2014/07/09 dog Hauts-de-Seine Urinary tract infection AmxStrKanGenTobChlSss
38356 2014/07/15 dog Aisne Otitis StrChlSssTmpNalEnr
38368 2014/08/21 dog Loire-Atlantique Urinary tract infection AmpC; ChlSssTmpNalEnr
38375 2014/08/21 dog Côtes-d’Armor Otitis AmpC; Chl
38653 2014/11/03 cat Seine-St-Denis Urinary tract infection StrKanGenTobChlSss
39081 2014/12/01 dog Val-de-Marne Urinary tract infection ESBL; StrKanAmkGenTobNetChlSssTmpNalEnr
39165 2014/10/02 cat Loire-Atlantique Urinary tract infection AmpC; SssTmpNalEnr
39175 2014/10/31 dog Val-de-Marne Otitis AmpC; AprChlNal
39193 2014/10/09 dog Paris Otitis AmpC; StrChlTmpNal
39214 2014/11/18 dog Val-de-Marne Skin infection AmpC; AprChlNal
39219 2015/01/26 dog Somme Unknown StrChlSssTmpNalEnr
39465c 2014/09/19 cat Gironde Unknown ESBL; SssTmpNalEnr
aESBL, extended-spectrum beta-lactamase; Amx, amoxicillin; Chl, chloramphenicol; Ffc, florfenicol; Amk, amikacin; Apr, apramycin; Gen, gentamicin; Tob, tobramycin;
Net, netilmicin; Kan, kanamycin; Str, streptomycin; Sss, sulfonamides; Tmp, trimethoprim; Nal, nalidixic acid; Enr, enrofloxacin. bFrench department: The department is
the administrative subdivision of France. cP. rettgeri strain.
frequently isolated from dogs, SGI1/PGI1 elements were more
prevalent in cats and horses. This would deserve confirmation
due to the low number of isolates collected from these two animal
categories.
Among the 11 SGI1-positive P. mirabilis, six showed an ESBL
phenotype using the double disk synergy test by antibiogram.
PCR mapping of the SGI1 resistance gene cluster and backbone
revealed that all six ESBL-positive isolates harbored the SGI1-
V variant carrying the blaVEB−6 gene (Figure 1). In the five
other SGI1-positive P. mirabilis isolates, PCR mapping of the
antimicrobial resistance gene cluster gave positive results for
different complex class 1 integrons, i.e., InSGI1-H, InPmABB
and InPmMAT (Figures 1, 2 and Table 1). PCR mapping of
the SGI1 backbone confirmed that SGI1 elements with InSGI1-
H, InPmABB, and InPmMAT harbored the same 2789 bp
deletion at position 5340-8120 (GenBank accession number
AF261825) in the region spanning from ORF S005 to ORF
S009, as previously described. Except for SGI1-InPmMAT, this
deletion was replaced by the insertion of ISVch4 (also called
IS1359) (Figure 1). Interestingly, this region contains two ORFs
S007 and S006 coding for homologs of the master activator
AcaDC of IncA/C conjugative plasmids and named SgaDC (SGI1
activator, subunits D and C; Poulin-Laprade et al., 2015; Muranyi
et al., 2016). The SgaDC activator (also named FlhDCSGI1) was
shown to be active on the same AcaDC-dependent promoter
regions, i.e., Pxis, and thus should be also implicated in transfer
and/or maintenance of SGI1 (Muranyi et al., 2016). The absence
of flhDCSGI1 in these variants and the partial deletion of
ORF S005 (traN) may have implications in their spread that
needs to be further studied. In addition to the classical penta-
resistance of SGI1 to amoxicillin, chloramphenicol, streptomycin
and sulphonamides, other SGI1/PGI1-conferred resistances
were amikacin, apramycin, gentamicin, tobramycin, netilmicin,
kanamycin, nalidixic acid, trimethoprim, and enrofloxacin.
The six PGI1-positive P. mirabilis isolates were characterized
by PCR mapping of the whole backbone. PCR products of
the expected sizes were obtained for the complete mapping
indicating a conserved PGI1 genetic structure in these isolates
(Figure 1). All six isolates showed similar antibiotic resistance
profiles as the ones previously described (Siebor and Neuwirth,
2014; Schultz et al., 2015). Interestingly PGI1, which was only
recently reported in P. mirabilis, was represented in more
than one-third of the genomic islands characterized here, thus
confirming the proportion observed in a recent study on a much
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smaller number of isolates (Schultz et al., 2015). This may suggest
either a previously undetected situation in the Proteae population
or a recent and rapid spread of PGI1 elements, which were
first described in 2014 (Siebor and Neuwirth, 2014). Our data
also indicate that the dissemination of SGI1/PGI1 in multidrug-
resistant P. mirabilis in animals is not a sporadic phenomenon
and should be considered with great attention.
Extended-Spectrum and AmpC
β-Lactamases
Eighteen strains (18/468, 3.8%) harbored an ESBL profile
(n = 9), an AmpC profile (n = 8), or a combination of
both (n = 1) after antibiotic susceptibility analysis. Only
one AmpC-producing strain did not present any additional
resistance (Table 1). Otherwise, proportions of strains
resistant to non-β-lactam antibiotics were particularly high
for chloramphenicol (14/18, 77.8%), streptomycin (10/18,
55.6%), trimethoprim/sulphonamides (13/18, 72.2%), nalidixic
acid (13/18, 72.2%), and enrofloxacin (10/18, 55.6%). Of note,
none of the strains were resistant to carbapenems.
In addition to the six SGI1-V positive P. mirabilis described
above, the ESBL phenotype was detected in four other strains.
Two P. mirabilis isolates (38327 and 39081) harbored the
blaVEB−6 gene independently of the SGI1 element (Figure 2),
whereas the two last ESBL-producing isolates harbored the
blaCTX−M−15 gene (P. mirabilis 34146) and the blaCTX−M−1
gene (P. rettgeri 39465). The prevalence of ESBL producers
was lower than the one recently reported in France. However,
the previous sampling was based on isolates conserved by the
veterinary laboratories and a bias toward non-susceptible isolates
cannot be excluded (Schultz et al., 2015). On the contrary, no
ESBL-producing isolate was detected in Japan (Harada et al.,
2014). In any case, Proteae from animal origin present much
less ESC-resistant isolates than those from human origin, since
the nowadays ESBL rate in animals is very close to the French
situation in human medicine in the late 1990s (Chanal et al.,
2000).
Concerning AmpC resistance phenotypes, the blaCMY−2
gene was detected alone in 7 P. mirabilis isolates whereas
another P. mirabilis isolate (38375) presented a blaDHA−16 gene
(Figure 2). Finally, one P. mirabilis isolate (39214) possessed
both blaCMY−2 and blaDHA−16 genes (Figure 2). The presence of
multiple ESC-resistance genes in two strains (blaVEB−6/blaCMY−2
in 38327 and blaCMY−2/blaDHA−16 in 39214) shows the capacity
of P. mirabilis to accumulate redundant resistance genes and thus
acting as a potential reservoir.
The chromosomal location of genes was assessed by Southern-
blots on I-CeuI-PFGE using the probes corresponding to the
ESBL/AmpC genes carried by the studied isolates, as well as
probes specific for the 23S rDNA. This method revealed that
all blaCMY−2 (Figure 3) and blaDHA−16 genes (Supplementary
Figure S1) were located on the bacterial chromosome. All
blaVEB−6 genes carried by the SGI1-V variant as well as the
blaVEB−6 gene identified in isolate 39081 were also proved to
be encoded by the chromosome (Supplementary Figure S2). On
the contrary, the plasmidic localization of genes was proved
by Southern-blots on S1-nuclease-PFGE using adequate probes.
The last non-chromosomal blaVEB−6 (38327; Supplementary
Figure S3) and blaCTX−M−1 (P. rettgeri 39465; Figure 4) genes
were thus shown to be carried on plasmids, which were
considered as non-typable because of the total absence of
amplification using the PBRT kit. Finally, the P. mirabilis isolate
34146 carried two copies of the ESBL gene blaCTX−M−15, one
FIGURE 3 | Chromosomal localization of blaCMY−2 in the relevant P. mirabilis isolates. (A) Whole genomic DNAs of isolates 34381 (lane1), 37665 (lane 2),
38327 (lane 3), 38368 (lane 4), 39165 (lane 5), 39175 (lane 6), 39193 (lane 7), and 39214 (lane 8) were digested with I-CeuI, and the restricted fragments subjected
to PFGE. DNA fragments were transferred to a nylon membrane and hybridized with probes specific to blaCMY−2 (B), and the 23S rRNA gene (C). The arrows
indicate the bands of interest.
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FIGURE 4 | Plasmidic localization of blaCTX−M−1 group genes in the
relevant isolates. (A) Whole genomic DNAs of a CTX-M-15-carrying E. coli
isolate used as a positive control (lane 1), P. mirabilis isolate 34146 (lane 2),
and P. rettgeri isolate 39465 (lane 3), were digested with S1-nuclease, and the
restricted fragments subjected to PFGE. DNA fragments were transferred to a
nylon membrane and hybridized with a probe specific to blaCTX−M (B). The
arrows indicate the bands of interest.
located on the chromosome and the other on a non-typable
plasmid (Figure 4). Whereas ESBL genes were mostly reported on
plasmids in Enterobacteriaceae, it is noteworthy to observe that it
is seemingly not the case in Proteae. These data strongly suggest
that Proteae may be more prone than other Enterobacteriaceae to
integrate resistance determinants into the chromosome, mostly
on SGI1/PGI1 or other genomic islands.
Genetic Diversity of the Isolates
SmaI PFGE revealed that all SGI1/PGI1-positive isolates were
genetically unrelated as were the ESBL/AmpC producing isolates
(Figure 2), except the six SGI1-V positive isolates that belonged
to the same cluster but interestingly differed from the ones
previously reported (Schultz et al., 2015). This clustering suggests
the spread of a clonal population among different and unrelated
individuals. Such a dominance of a clonal population of SGI1-
V/blaVEB−6 P. mirabilis strains in humans and companion
animals may result from close contacts between these two
populations, as also demonstrated for the transfer of other
multidrug resistant bacteria or plasmids, such as those carrying
ESBL genes. Indeed, the transmission of bacterial clones from
animals to humans (or vice-versa) through physical contacts or
contact with contaminated saliva or feces has been described
(Espinosa-Gongora et al., 2015; Ljungquist et al., 2016).
CONCLUSION
In this study, we showed a significant prevalence rate (∼4%)
of ESBLs/AmpC in P. mirabilis of animal sources. A long-
term survey is now needed to decipher whether these are
emerging phenotypes or only sporadic cases. The multidrug
resistance genomic islands SGI1 and PGI1 play a major role in
the dissemination of ESBLs/AmpC genes as well as other non-
β-lactam resistance genes. Moreover, we report the spread of
the SGI1-V/blaVEB−6-carrying P. mirabilis clonal population to
horses. This peculiar ESBL-producing P. mirabilis population
was previously recognized in humans and dogs and highly
suspected in poultry isolates (Seiffert et al., 2013). Altogether,
these data suggest an inter-transmission pathway of public
health relevance that needs further investigations to be clarified.
Therefore, P. mirabilis should be regarded as a potential reservoir
of resistance traits in companion animals making us believe that
veterinarians should pay more attention to P. mirabilis as an
opportunistic multidrug-resistant pathogen.
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